The Impact of Adjuvant Therapy for Breast Cancer on Cognitive Function: Current Evidence and Directions for Research

Seminars in Oncology

Volumn 30, Issue 6, 2003, Pages 749-762

  Rugo, Hope S ^a   Ahles, Tim ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ERYTHROPOIETIN; FLUOROURACIL; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; METHYLPHENIDATE; METHYLPREDNISOLONE; PACLITAXEL; TAMOXIFEN; VINCRISTINE;

ANXIETY DISORDER; BRAIN DISEASE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CEREBELLUM DISEASE; COGNITION; COGNITIVE DEFECT; DEPRESSION; DISEASE PREDISPOSITION; DOSE RESPONSE; EVIDENCE BASED MEDICINE; FATIGUE; FUNCTIONAL ASSESSMENT; HUMAN; LEUKOENCEPHALOPATHY; MEMORY DISORDER; NEUROPATHY; NEUROPSYCHOLOGY; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; TREATMENT PLANNING;

EID: 0345732633     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2003.09.008     Document Type: Article

References (95)

1. Baum M, Ravdin PM: Decision-making in early breast cancer: Guidelines and decision tools. Eur J Cancer 38:745-749, 2002
2. Whelan T, Sawka C, Levine M, et al: Helping patients make informed choices: A randomized trial of a decision aid for adjuvant chemotherapy in lymph node-negative breast cancer. J Natl Cancer Inst 95:581-587, 2003
3. Langer AS: Side effects, quality-of-life issues, and trade-offs: The patient perspective. J Natl Cancer Inst Monogr 30:125-129, 2001
4. Jansen SJ, Kievit J, Nooij MA, et al: Patients' preferences for adjuvant chemotherapy in early-stage breast cancer: Is treatment worthwhile? Br J Cancer 84:1577-1585, 2001
5. Lindley, C, Vasa S, Sawyer W, et al: Quality of life and preferences for treatment following systemic adjuvant therapy for early stage breast cancer. J Clin Oncol 16:1380-1387, 1998
6. Silberfarb PM, Philibert D, Levine PM: Psychosocial aspects of neoplastic disease: II. Affective and cognitive effects of chemotherapy in cancer patients. Am J Psychiatry 137:597-601, 1980
7. Oxman TE, Silberfarb PM: Serial cognitive testing in cancer patients receiving chemotherapy. Am J Psychiatry 137: 1263-1265, 1980
8. Ahles TA, Saykin A: Cognitive effects of standard-dose chemotherapy in patients with cancer. Cancer Invest 19:812-820, 2001
9. Meyers CA: Neurocognitive dysfunction in cancer patients. Oncology (Huntingt) 14:75-79, 2000
10. Brown PD, Buckner JC, O'Fallon JR, et al: Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the Folstein Mini-Mental State Examination. J Clin Oncol 21:2519-2524, 2003
11. Ahles TA, Silberfarb PM, Herndon J, et al: Psychologic and neuropsychologic functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin: A study by the Cancer and Leukemia Group B. J Clin Oncol 16:1954-1960, 1998
12. Goodwin PJ, Black JT, Bordeleau LJ, et al: Health-related quality-of-life measurement in randomized clinical trials in breast cancer - Taking stock. J Natl Cancer Inst 95:263-281, 2003
13. Phillips KA, Bernhard J: Adjuvant breast cancer treatment and cognitive function: Current knowledge and research directions. J Natl Cancer Inst 95:190-197, 2003
14. Ahles TA, Saykin AJ: Breast cancer chemotherapy-related cognitive dysfunction. Clin Breast Cancer 3:S84-90, 2002 (suppl 3)
15. Olin JJ: Cognitive function after systemic therapy for breast cancer. Oncology (Huntingt) 15:613-618, 2001
16. Ganz PA: Cognitive dysfunction following adjuvant treatment of breast cancer: A new dose-limiting effect? J Natl Cancer Inst 90:182-183, 1998
17. Wesnes K: Assessing cognitive function in clinical trials: Latest developments and future directions. Drug Discov Today 7:29-35, 2002
18. President's Cancer Panel: Cancer care issues in the United States: Quality of care, quality of life. Report of the Chairman, President's Cancer Panel, 1988. Bethesda, MD, National Cancer Program, National Cancer Institute, 1999 (available on-line)
19. Ferrell BR, Hassey Dow K: Quality of life among long-term cancer survivors. Oncology (Huntingt) 11:565-576, 1997
20. Cimprich B: Pretreatment symptom distress in women newly diagnosed with breast cancer. Cancer Nurs 22:185-194, 1999
21. Cimprich B, Ronis DL: Attention and symptom distress in women with and without breast cancer. Nurs Res 50:86-94, 2001
22. Lee-Jones C, Humphris G, Dixon R, et al: Fear of cancer recurrence - A literature review and proposed cognitive formulation to explain exacerbation of recurrence fears. Psychooncology 6:95-105, 1997
23. Bower JE, Ganz PA, Desmond KA, et al: Fatigue in breast cancer survivors: Occurrence, correlates, and impact on quality of life. J Clin Oncol 18:743-753, 2000
24. Valentine AD, Meyers CA, Talpaz M: Treatment of neurotoxic side effects of interferon-alpha with naltrexone. Cancer Invest 13:561-566, 1995
25. Bender CM, Paraska KK, Sereika SM, et al: Cognitive function and reproductive hormones in adjuvant therapy for breast cancer: A critical review. J Pain Symptom Manage 21:407-424, 2001
26. Schagen SB, van Dam FS, Muller MJ, et al: Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 85:640-650, 1999
27. Ahles TA, Saykin AJ, Furstenberg CT, et al: Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 20:485-493, 2002
28. Meyers CA, Wefel JS: The use of the Mini-Mental State Examination to assess cognitive functioning in cancer trials: No ifs, ands, buts, or sensitivity. J Clin Oncol 21:3557-3558, 2003
29. Barton D, Loprinzi C: Novel approaches to preventing chemotherapy-induced cognitive dysfunction in breast cancer: The art of the possible. Clin Breast Cancer 3:S121-127, 2002 (suppl 3)
30. Wieneke MH, Dienst ER: Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psychooncology 4:61-66, 1995
31. van Dam FS, Schagen SB, Muller MJ, et al: Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: High-dose versus standard-dose chemotherapy. J Natl Cancer Inst 90:210-218, 1998
32. Aaronson NK, Ahmedzi S, Bergman B, et al: The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
33. Ibbotson T, Maguire P, Selby P, et al: Screening for anxiety and depression in cancer patients: The effects of disease and treatment. Eur J Cancer 30A:37-40, 1994
34. Schagen SB, Muller MJ, Boogerd W, et al: Late effects of adjuvant chemotherapy on cognitive function: A follow-up study in breast cancer patients. Ann Oncol 13:1387-1397, 2002
35. Brezden CB, Phillips KA, Abdolell M, et al: Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 18:2695-2701, 2000
36. Faust D, Fogel BS: The development and initial validation of a sensitive bedside cognitive screening test. J Nerv Ment Dis 177:25-31, 1989
37. McNair DM, Lorr M, Droppleman LF: Edits Manual for the Profile of Mood States. Edits/Educational and Industrial Testing Service, San Diego, CA, 1992
38. Wagner LI, Cella D, Cashy AH, et al: Single item screening to detect clinically significant fatigue, pain, distress and anorexia in ambulatory oncology practice. Proc Am Soc Clin Oncol 22:2122, 2003 (abstr)
39. Tannock I, Tchen N, Juffs H, et al: Fatigue, menopausal symptoms and cognitive dysfunction associated with adjuvant chemotherapy: First year results of a large prospective controlled study. Breast Cancer Res Treat 76:549, 2002 (abstr)
40. Woo B, Dibble SL, Piper BF, et al: Differences in fatigue by treatment methods in women with breast cancer. Oncol Nurs Forum 25:915-920, 1998
41. Valentine AD, Meyers CA: Cognitive and mood disturbance as causes and symptoms of fatigue in cancer patients. Cancer 92:1694-1698, 2001
42. Lezak M: Neuropsychological Assessment. New York, NY, Oxford Press, 1995
43. Tuxen MK, Hansen SW: Neurotoxicity secondary to antineoplastic drugs. Cancer Treat Rev 20:191-214, 1994
44. Choi SM, Lee SH, Yang YS, et al: 5-Fluorouracil-induced leukoencephalopathy in patients with breast cancer. J Korean Med Sci 16: 328-334; 2001
45. Cleeland CS, Bennett GJ, Dantzer R, et al: Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer 97:2919-2925, 2003
46. Bower JE, Ganz PA, Aziz N, et al: T-cell homeostasis in breast cancer survivors with persistent fatigue. J Natl Cancer Inst 95:1165-1168, 2003
47. Roses AD: Apolipoprotein E, a gene with complex biological interactions in the aging brain. Neurobiol Dis 4:170-186, 1997
48. Friedman G, Froom P, Sazbon L, et al: Apolipoprotein E-[epsilon]4 genotype predicts a poor outcome in survivors of traumatic brain injury. Neurology 52:244-248, 1999
49. Liberman JN, Stewart WF, Wesnes K, et al: Apolipoprotein E-[epsilon]4 and short-term recovery from predominantly mild brain injury. Neurology 58:1038-1044, 2002
50. Haan MN, Shemanski L, Jagust WJ, et al: The role of APOE E4 in modulating effects of other risk factors for cognitive decline in elderly persons. JAMA 282:40-46, 1999
51. Bretsky P, Guralnik JM, Launer L, et al: The role of APOE-epsilon4 in longitudinal cognitive decline: MacArthur Studies of Successful Aging. Neurology 60:1077-1081, 2003
52. Ahles TA, Saykin AJ, Noll WW, et al: The relationship of APOE genotype to neuropsychological perfomance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology 12:612-619, 2003
53. Sherwin BB: Estrogen and cognitive functioning in women. Endocr Rev 24:133-151, 2003
54. LeBlanc ES, Janowsky J, Chan BKS, et al: Hormone replacement therapy and cognition: Sytematic review and meta-analysis. JAMA 285:1489-1499, 2001
55. Hogervorst E, Yaffe K, Richards M, et al: Hormone replacement therapy for cognitive function in postmenopausal women. Cochrane Database Syst Rev CD003122, 2002
56. Grady D, Yaffe K, Kristof M, et al: Effect of postmenopausal hormone therapy on cognitive function: The Heart and Estrogen/progestin Replacement Study. Am J Med 113:543-548, 2002
57. Cockrell JR, Folstein MF: Mini-Mental State Examination (MMSE). Psychopharmacol Bull 24:689-692, 1988
58. Yaffe K, Lui LY, Grady D, et al: Cognitive decline in women in relation to non-protein-bound oestradiol concentrations. Lancet 356:708-712, 2000
59. Rapp SR, Espeland MA, Shumaker SA, et al: Effect of estrogen plus progestin on global cognitive function in postmenopausal women: The Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 289:2663-2672, 2003
60. Shumaker SA, Legault C, Thal L, et al: Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Women's Health Initiative Memory Study: A randomized controlled trial. JAMA 289: 2651-2662, 2003
61. Yaffe K, Haan M, Byers A, et al: Estrogen use, APOE, and cognitive decline: Evidence of gene-environment interaction. Neurology 54:1949-1954, 2000
62. Paganini-Hill A, Clark LJ: Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 64:165-176, 2000
63. Yaffe K, Krueger K, Sarkar S, et al: Cognitive function in postmenopausal women treated with raloxifene. N Engl J Med 344:1207-1213, 2001
64. Ernst T, Chang L, Cooray D, et al: The effects of tamoxifen and estrogen on brain metabolism in elderly women. J Natl Cancer Inst 94:592-597, 2002
65. Ganz PA, Castellon SA, Silverman DH: Estrogen, tamoxifen, and the brain. J Natl Cancer Inst 94:547-549, 2002
66. Buzdar A: Anastrozole as adjuvant therapy for early-stage breast cancer: Implications of the ATAC trial. Clin Breast Cancer 4:S42-48, 2003 (suppl 1)
67. Bulun SE, Zeitoun K, Sasano H, et al: Aromatase in aging women. Semin Reprod Endocrinol 17:349-358, 1999
68. Jenkins VA, Fallowfield LJ, Schilling V, et al: Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? Breast Cancer Res Treat 76:548, 2002 (abstr)
69. Royall DR, Mulroy AR, Chiodo LK, et al: Clock drawing is sensitive to executive control: A comparison of six methods. J Gerontol B Psychol Sci Soc Sci 54:P328-333, 1999
70. Royall DR, Lauterbach EC, Cummings JL, et al: Executive control function: A review of its promise and challenges for clinical research. A report from the Committee on Research of the American Neuropsychiatric Association. J Neuropsychiatry Clin Neurosci 14:377-405, 2002
71. Royall DR, Rauch R, Roman GC, et al: Frontal MRI findings associated with impairment on the Executive Interview (EXIT25). Exp Aging Res 27:293-308, 2001
72. Collie A, Maruff P, Makdissi M, et al: CogSport: Reliability and correlation with conventional cognitive tests used in postconcussion medical evaluations. Clin J Sport Med 13: 28-32, 2003
73. Darby D, Maruff P, Collie A, et al: Mild cognitive impairment can be detected by multiple assessments in a single day. Neurology 59:1042-1046, 2002
74. Schagen SB, Hamburger HL, Muller MJ, et al: Neurophysiological evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function. J Neurooncol 51:159-165, 2001
75. Silverman DH, Castellon SA, Abraham L, et al: Abnormal regional brain metabolism in breast cancer survivors after adjuvant chemotherapy is associated with cognitive changes. Proc Am Soc Clin Oncol 22:47, 2003 (abstr)
76. Saykin AJ, Ahles TA, Schoenfeld JD, et al: Gray matter reduction on voxel-based morphometry in chemotherapy-treated cancer survivors. J Int Neuropsychol Soc 9:246, 2003 (abstr)
77. Ferguson RJ, Ahles TA: Low neuropsychologic performance among adult cancer survivors treated with chemotherapy. Curr Neurol Neurosci Rep 3:215-222, 2003
78. Antoni MH, Antoni MH, Carver CS: Cognitive behavioral stress management intervention and positive psychological changes in breast cancer patients after surgery and their physiological correlates. Proc Am Soc Clin Oncol 22:3064, 2003 (abstr)
79. Cruess DG, Antoni MH, McGregor BA, et al: Cognitive-behavioral stress management reduces serum cortisol by enhancing benefit finding among women being treated for early stage breast cancer. Psychosom Med 62:304-308, 2000
80. Gall TL, Comblat MW: Breast cancer survivors give voice: A qualitative analysis of spiritual factors in long-term adjustment. Psychooncology 11:524-535, 2002
81. Masuda S, Oakano M, Yamagishi K, et al: A novel site of erythropoietin productin. Oxygen-dependent production in cultured rat astrocytes. J Biol Chem 269:19488-19493, 1994
82. Eid T, Brines M: Recombinant human erythropoietin for neuroprotection: What is the evidence? Clin Breast Cancer 3:S109-115, 2002 (suppl 3)
83. Cerami A, Brines ML, Ghezzi P, et al: Effects of epoetin alfa on the central nervous system. Semin Oncol 28:66-70, 2001
84. Brines ML, Ghezzi P, Keenan S, et al: Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 97:10526-10531, 2000
85. Ehrenreich H, Hasselblatt M, Dembowski C, et al: Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 8:495-505, 2002
86. Dawson TM: Preconditioning-mediated neuroprotection through erythropoietin? Lancet 359:96-97, 2002
87. O'Shaughnessy J, Vukelja S, Savin M, et al: Impact of epoetin alfa on cognitive function, asthenia, and quality of life in women with breast cancer receiving adjuvant or neoadjuvant chemotherapy: Analysis of 6-month follow-up data. Breast Cancer Res Treat 76:550, 2002 (abstr)
88. O'Shaughnessy JA: Effects of epoetin alfa on cognitive function, mood, asthenia, and quality of life in women with breast cancer undergoing adjuvant chemotherapy. Clin Breast Cancer 3:S116-120, 2002 (suppl 3)
89. Leyland-Jones B: Reflection and reaction. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet 4:459-460, 2003
90. Hencke M, Laszig R, Rube C, et al: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomized, double-blind, placebo-controlled trial. Lancet 363:1255-1260, 2003
91. Arcasoy MO, Amin K, Karayal AF, et al: Functional significance of erythropoietin receptor expression in breast cancer. Lab Invest 82:911-918, 2002
92. Yasuda Y, Fujita Y, Matsuo T, et al: Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 24:1021-1029, 2003
93. Meyers CA, Weitzner MA, Valentine AD, et al: Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol 16:2522-2527, 1998
94. Thompson SJ, Leigh L, Christensen R, et al: Immediate neurocognitive effects of methylphenidate on learning-impaired survivors of childhood cancer. J Clin Oncol 19:1802-1808, 2001
95. Kennedy DO, Scholey AB, Wesnes KA: Modulation of cognition and mood following administration of single doses of Ginkgo biloba, ginseng, and a ginkgo/ginseng combination to healthy young adults. Physiol Behav 75:739-751, 2002